Arenaviridae exoribonuclease presents genomic RNA edition capacity.

Elsie Yekwa[1,2,4], Chutima Aphibanthammakit[2,5], Xavier Carnec[3], Caroline Picard[3], Bruno Canard[1,2,6], Sylvain Baize[3], François Ferron[1,2,6*]

[1] CNRS, AFMB UMR 7257, 13288, Marseille, France

[2] Aix-Marseille Université, AFMB UMR 7257, 13288, Marseille, France

[3] Unité de Biologie des Infections Virales Emergentes, Institut Pasteur; Centre International de Recherche en Infectiologie (INSERM, CNRS, ENS Lyon, Université Lyon I), Lyon, France

[4] Current address : Division of Medical Virology, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg, South Africa

[5] Current address : UMR 1208 Ingénierie des Agropolymères et Technologies Emergentes, Université de Montpellier- SupAgro-INRA-CIRAD, 2 Place Pierre Viala, Montpellier 34060 Cedex 1, France

[6] European Virus Bioinformatics Center, Leutragraben 1, 07743 Jena, Germany.

*Corresponding author : francois.ferron@afmb.univ-mrs.fr

Abstract

The *Arenaviridae* is a large family of viruses causing both acute and persistent infections and causing significant public health concerns in afflicted regions. A “trademark” of infection is the quick and efficient immuno-suppression mediated in part by a 3’-5’ RNA exonuclease domain (ExoN) of the Nucleoprotein (NP). Mopeia virus, the eastern African counterpart of Lassa virus, carries such ExoN domain, but does not suppress the host innate immunity. We have recently reported the crystal structure of the Mopeia virus ExoN domain, which presents a conserved fold and active site. In the present study, we show that the ExoN activity rules out a direct link between ExoN activity and alteration of the host innate immunity. We found that the Arenavirus ExoN, however, is able to excise mis-incorporated bases present at the 3’-end of double stranded RNA. ExoN(-) arenaviruses cultured in cells dampened in innate immunity still replicated in spite of a significant reduction in the viral charge over several passages. The remaining ExoN(-) virus population showed an increased base substitution rate on a narrow nucleotide spectrum, linking the ExoN activity to genome editing. Since, the Arenavirus ExoN belongs to the same nuclease family as that of the nsp14 coronavirus ExoN ; which has been recently shown to promote viral RNA synthesis proofreading; we propose that Arenavirus ExoN is involved in a “limited RNA editing” mechanism mainly controlled by structural constraints and a low mutational/fitness ratio.

Author summary

Only *Arenaviridae* and *Coronaviridae* encode a 3’-5’ RNA exonuclease domain (ExoN) in their genome. This activity is either used to counteract the innate immunity response during viral infection or to ensure genome stability during replication. Mopeia virus (MOPV), the eastern African counterpart of Lassa virus, carries such ExoN domain, but does not suppress the host innate immunity. We studied MOPV ExoN activity both *in vitro and in cellula* to assess the role of ExoN

MOPV and found that the Arenaviral ExoN is fully active on dsRNA, and is able like the one of *Coronaviridae* to excise a mismatched base. We measured genetic stability and found evidence of a limited spectrum of RNA synthesis proofreading mechanism, together with a strongly impacted viral replication. We propose that the Arenaviral ExoN is involved in a functional check of the conserved RNA structures of the viral genome.

Introduction

Arenaviridae is a family of viruses that cause chronic infections of rodents and constitutes a reservoir of human pathogens across the world [1]. Already with a global distribution Lymphocytic choriomeningitis virus (LCMV) is the prototypic member of the family; it is one of the most studied virus and still an underestimated threat to human health [2–6]. In South America, Machupo, Guanarito, Junin, Sabia, and Chapare viruses are responsible for hemorrhagic fever [7] while in Africa Lujo [8] and Lassa viruses (LASV) constitutes a major public health concern [9–13]. Indeed, LASV is responsible for several hundred thousand infections per year alone [14]. It is a common endemic infection in West Africa (Sierra Leone, Guinea, Liberia, Nigeria) responsible for hearing loss, tremors and encephalitis [13,15]. Moreover, this endemic infection frequently spikes a high number of Lassa fever cases associated with significant mortality and high morbidity. The last episode started in February 2018, in the Niger delta region, presents a case fatality rate around 25 % [16]. This new epidemic reinforces the trends observed during the recent epidemics in Nigeria and Benin in January 2016 [17,18], indicating an increase in virulence, an expansion of spreading areas and the number of cases [19]. Humans become infected through contact with infected rodent excreta, tissues, or blood. Person-to-person transmission of Lassa fever can also occur particularly in the hospital environment in the absence of adequate infection control measures [20]. Until now, no licensed vaccine is available, and therapeutic options are limited to early administration of

ribavirin. Despite its public health significance, and recent major contributions [21–25], *Arenaviridae* biology is still poorly understood.

Arenaviridae are negative-sense single-stranded RNA segmented viruses, with a genome consisting of two segments L (~7.2 kb) and S (~3.4 kb). Each segment has an ambisense coding mechanism, encoding two proteins in opposite orientation, separated by an intergenic region (IGR). The L RNA segment encodes a large protein L (~200 kDa) and a small disordered protein Z (~ 11 kDa) [1]. L is a multi-domain protein including in its N-terminus an endonuclease domain followed by a polymerase domain and in its C-terminus a cap binding like domain (for review [26]). Z, which contains a RING finger motif, is a multifunction protein regulating the life cycle of the virus and during budding assembles to form the matrix [27–29]. The S RNA encodes the precursor of mature virion glycoprotein GP-C (75 kDa); that will give after post-translational cleavage GP-1 (40 to 46 kDa) and GP-2 (35 kDa) [30,31]; and nucleoprotein NP (~ 63 kDa) [25,32]. NP forms a polymer protecting the genomic (and anti-genomic) RNA (RNA_v) [33]. L and NP together with RNA_v form an active ribonucleic complex (RNP) for replication and transcription [34]. In addition to this critical function, NP is involved in clearing off the cytoplasm of double stranded RNAs ($_{ds}$RNA), through its C-terminal exonuclease domain (ExoN) [25,32,35–37]. These $_{ds}$RNAs are markers of viral infection in the cell and are triggering host innate immunity response. Indeed, when $_{ds}$RNA is detected by proteins such as retinoic acid-inducible I (RIG-I) or melanoma differentiation-associated 5 (MDA- 5), it initiates a signaling pathway that result in the translocation of interferon (IFN) regulatory factor 3 (IRF-3) to the nucleus [38,39]. Then, IRF-3 activates the expression of IFN-α/β, which initiates the antiviral response in the infected cells and primes neighboring cells for a rapid response to viral invasion. From a modular (sequence and structure) perspective, all NP presents a C-terminal ExoN domain (S1 Fig). The South Eastern African counterpart of Lassa Virus is Mopeia virus (MOPV) [40], a non-pathogenic virus. The NP of these two viruses presents a high

sequence identity of about 73%, but contrary to Lassa virus, MOPV infection does not result in innate immunity suppression [41,42] leading us to suspect that the domain was not fully functional against $_{ds}$RNA. Recent studies reported the structure of Mopeia ExoN domain [43] and evidence of an ExoN activity in NP of MOPV, essential for multiplication in antigen-presenting cells [44]. The observed fold conservation and activity raises questions about the biological role of the NP-exo MOPV, and whether it could be conserved for other functional or structural reasons [26]. In the DNA world, ExoNs are mainly involved in mechanisms of genome stability and error correction during or after DNA synthesis. Yet, in viral RNA world, the existence of ExoN is of rare occurrence as only two families of viruses possess a 3'-5' ExoN member of the DEDD super family: *Arenaviridae* and *Coronaviridae* [25,45–47]. The Coronavirus ExoN is part of the nsp14 protein, associated to the main replicative RNA-dependent polymerase nsp12. During RNA synthesis, nsp14 belongs to the replication/transcription complex (RTC), excises mismatched bases occurring during processive RNA synthesis, and contributes to overall RNA synthesis fidelity [47–51].

Having noted the structural and functional relatedness of *Arenaviridae* ExoN to the *Coronaviridae* ExoN, we engaged into mechanistic studies of the MOPV ExoN. Here, we present a detailed characterization of the activity of NP-exo MOPV including substrate specificity and ion dependency, compared to the one of LCMV. We show that the *Arenaviridae* ExoN is active on 3' mismatched $_{ds}$RNA substrate mimicking a stalled RNA synthesis intermediate, in a remarkable substrate requirement similarity to Coronavirus nsp14. We report, however, that a mutated NP-exo MOPV abrogating the ExoN activity does not lead to an overall higher mutation rate in the surviving viruses, but rather drastically reduces the number of infectious viruses while increasing the release of non-infectious material from infected cells. Interestingly, few nucleotide substitution types appear to be significantly increased in the ExoN(-), establishing that ExoN is active on its own genomic RNA. All together these results confer potentially significant roles to the ExoN

domain in the *Arenaviridae* life cycle.

Material and Methods

Cloning, mutagenesis, protein production and purification

cDNA corresponding to NP ExoN domain of : MOPV (residues 365-570 - P19239), LCMV (residues 357-559 - NP_694852) were cloned into the pETG20A expression vector using the Gateway® method (Invitrogen), which adds a cleavable thioredoxin-hexahistidine tag at the N-terminus. The integrity of the DNA construct was verified by DNA sequencing. The sequences of the primers used to sub cloned each domain were:

LCMV forward:

GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTACTTCCAGGGTTTAAGCTACAGCCAGACAATGCTTTTAAA ,

LCMV reverse:

GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATTATGTCACATCATTTGGGCCTCTA ,

MOPV forward:

GGGGACAAGTTTGTACAAAAAAGCAGGCTTAGAAAACCTGTACTTCCAGGGTTTAACCTACTCTCAGACAATGGA,

MOPV reverse:

GGGGACCACTTTGTACAAGAAAGCTGGGTCTTATTACAGGACAACTCTGGGA.

Plasmids were used to transformed *E.coli* strain C2566 (NEB) protease-deficient and carrying pRARE plasmid (Novagen). Bacteria were grown in LB medium (AthenaES) at 37°C to an $OD600_{nm}$ of 0.5. Expression was induced with 0.5 mM IPTG, and bacteria were grown shaking at

210 rpm overnight at 17°C in presence of 100µM of $ZnCl_2$. Bacteria were pelleted, frozen, and stored at -80°C.

The three domains were purified at 4°C. Frozen pellet were melted on ice, resuspended in lysis buffer (20mM HEPES pH7.5, 300 NaCl, 5 mM imidazole, 5% glycerol, 0,1 mg/ml lysozyme and 50 µg Dnase), sonicated, and the lysate was cleared by centrifugation at 20,000 rpm for 30 min. Each protein was first purified by metal affinity chromatography using 2ml of His pur™ cobalt column (Thermo Scientific). The tag was removed by cleavage with TEV protease followed by purification on a second cobalt affinity chromatography. Proteins were further purified by gel filtration using superdex 75 column (GE Healthcare) in 20 mM HEPES pH 7.5, 300 mM NaCl, 2 mM $MgCl_2$ and 5% glycerol.

Mutants were generated for each domain by introducing single point mutations using the Quick change site-directed mutagenesis kit (Stratagene). The primer sequences used for mutagenesis are listed in the supplementary S1 Table. The presence of *ad hoc* mutations and the integrity of the complete coding region of each mutant were confirmed by sequencing. All the mutants were expressed and purified following the established protocol.

RNA labeling and preparation

Synthetic RNAs used in this study were purchased from Dharmacon or Biomers (HPLC grade). They are listed in S2 Table and their predicted structures are shown in S2 Fig. All sens RNA strands were labeled at their 5' end with [γ-^{32}P] ATP using protein nucleotide kinase (NEB) according to the manufacturer's instructions. For experiments involving overhang mismatched $_{ds}$RNA, the $_{ds}$RNAs were generated by annealing an anti-sense RNA strand containing 3'-phosphate modifications with its 5'-radioactively labeled sens RNA strand. The annealing condition was, heating at 70 °C for 10 min and then cooling down to room temperature (with a primer/template

ratio of 1.2:1).

Exonuclease activity assay.

Reactions were carried out in a buffer containing 20 mM Tris-Hcl, 5 mM $MnCl_2$ (unless specified by 5 mM of: $MgCl_2$, $CaCl_2$, or $ZnCl_2$) and 5 mM DTT. Standard reactions contained 0,25 µM of protein (NP-exo MOPV or LCMV or mutants) and 1,25 µM of radiolabeled RNA substrate. After incubated at 37°C, the reactions were quenched at intervals between 0 and 30 minutes by the addition of an equal volume of loading buffer (formamide containing 10mM EDTA). The products were heated at 70°C for 5 minutes, rapidly cooled on ice for 3 minutes followed by separation in a 20% poly-acrylamide gel containing 8 M urea and buffered with 0,5X Tris-borate-EDTA. Gels were exposed overnight to a phosphor screen and then visualized with a phosphoimager FLA-3000 (Fuji). Total RNA degradation products were quantified using Image Guage (Fuji), the speed of cleavage determined and graphs plotted using GraphPad PRISM version 6.0. Experiments were carried out at least in triplicate and only representative gels are shown.

Thermal shift assay.

A real-time PCR set-up (Bio-rad) was used to monitor the thermal unfolding of the ExoN domain of NP -MOPV or LCMV alone or in the presence of different divalent ions Mn^{2+}, Mg^{2+}, Ca^{2+} and Zn^{2+}. Proteins were equilibrated in a buffer containing 20 mM HEPES pH 7.5, 300 mM NaCl, 5% glycerol. All reactions were set up in a final volume of 25 µl in a 96-well plate with total protein concentration of 1,8 mg/ml, 1x SYPRO Orange and incubated with or without 5 mM of metal ions. The PCR plates were sealed with optical sealing tape (Bio-rad) and incubated in the PCR machine for 2 minutes at 20°C followed by 0,2°C increments to a final temperature of 95°C. Thermal denaturation was monitored using SYPRO Orange (Life Technologies) and the fluorescent

intensities were measured at 490 nm excitation and 530 nm emission wavelengths. The unfolding of proteins was monitored by following the increase in fluorescence of the probe as it binds to exposed hydrophobic regions of the denatured protein. The Tm was then calculated as the mid-log of the transition phase of the florescence curve using the Boltzmann equation. All measurements were performed in triplicates.

Structure and sequence analysis

Structure and sequence comparison of Arenavirus exonuclease with other viral exonuclease.

Structure similarities were search with PDBeFold [52] using the MOPV exonuclease domain as a search model (PDB : 5LRP). Corresponding sequences were aligned based on structure comparison using Expresso [53]. Figures were generated with the programs ESPript-ENDscript [54], WebLogo server [55] and UCSF chimera [56].

Sequence retrieval of mammarenavirus L and analysis.

All annotated complete protein sequences of Mammarenaviruses L protein were downloaded from NCBI. The dataset of 559 sequences was manually curated using Jalview [57] in order to remove Identical, mis-annotated or complete sequences with undefined amino acid (X). The remaining 395 sequences were aligned using MUSCLE [58] constituting the *Mammarenavirus* (MAMV) dataset. From this latter two dataset are being derived the Mopeia virus dataset of 12 sequences, and the Lassa Virus dataset of 277 sequences, as being the closest homologue of Mopeia virus with a large number of sequences. Amino acid composition (%) for position in the sequence corresponding to the Mopeia emerging mutant were calculated with Jalview and represented using WebLogo [55] for the three datasets.

Viral infection and genome sequencing.

The MOPV strain AN21366 (JN561684 and JN561685) was used to establish the reverse genetics system for MOPV. The detailed procedures for virus rescue, production, titration and infection of Vero E6 cells (VERO C1008 [Vero 76, clone E6, Vero E6] ATCC® CRL-1586™ (ATCC, LGC Standards, Molsheim, France) are described in [44]. In brief, the recombinant NP-exo WT and mutant (D390A/G393A) MOPV were used to infect Vero E6 cells using a MOI of 0.01. Supernatants were collected four days post infection. Viral production/titration/infection were repeated iteratively for 10 times. For viral titration, the presence of the viruses was revealed by immunostaining in infected cells with a polyclonal rabbit antibody that recognizes the MOPV Z protein (Agrobio, France) and a phosphatase alkaline-conjugated polyclonal goat anti-rabbit antibody (Sigma) and 1-Step NBT/BCIP substrate (Thermo Fisher scientific, Waltham, MA). Results are expressed in Focus Forming Unit per mL (FFU/mL). For RNA quantification, viral RNA were extracted from cell culture supernatants (Qiagen, Courtaboeuf, France) and quantification was performed with the EuroBioGreen qPCR Mix Lo-ROX (Eurobio, Les Ulis, France), using an in house developed assay with 5’-CTTTCCCCTGGCGTGTCA-3’ and 5’-GAATTTTGAAGGCTGCCTTGA-3’ primers. Deep sequencing analysis of viral genomes was performed as described in [44].

Results

The MOPV NP-exo exhibits a metal-dependent 3'-5' ExoN activity.

The ExoN domain of NP-MOPV (NP-exo MOPV) was incubated with a 5' radiolabeled 22 nt RNA hairpin (HP4, S2A Fig) whose 3'-end is base-paired into a double stranded RNA. The reaction was stopped at intervals of 0.1 , 5 and 30 minutes (Fig 1A). In the presence of Mg^{2+}, NP-

exo MOPV is able to cleave this stable RNA hairpin (DG=-14.7 kcal/mole) predominantly down to a 18-mer product. After removing the 1st 4 nucleotides, degradation stops at the loop region. A similar experiment in the presence of Mn^{2+} allows further degradation into the loop, whereas ExoN is inactive in the presence of either Zn^{2+} or Ca^{2+}. The laddering degradation pattern visualized on the gel, together with radio-label quantification indicate that it acts in the 3'-5' direction (S2B Fig). Visual examination of degradation kinetics shows, a band-product accumulation prior to G nucleotides, indicating that the latter are slower to remove than Cs. We also tested the ExoN activity of the ExoN domain of NP-LCMV (NP-exo LCMV) (Fig 1A) on the same RNA substrate. Both proteins cleave the RNA following a similar degradation pattern and comparable kinetics (S2B Fig and S3 Table). The two ExoNs exhibit their highest activity in the presence of Mn^{2+}, followed by Mg^{2+} and they are inactive in the presence of either Ca^{2+} or Zn^{2+} or EDTA (Fig 1A). These results show that the nature of the ions is altering the ExoN activity and its associated pattern of degradation can be greatly modulated by the nature of the metal ion co-factor.

Stabilizing effect by ion cofactor is not correlatable to NP-exo activity.

To study the effect of divalent metal binding on the stability of NP-exo MOPV, we measured the change in melting temperature (Tm) by a Thermal Shift Assay (TSA) in the presence of 5 mM of several metal ions. NP-exo MOPV without metal ions has a Tm of 49.4 °C. Positive Tm shifts are observed in the presence of $MnCl_2$ (+16.5 °C), $MgCl_2$ (+4.9 °C), $CaCl_2$ (+7.5 °C) and a slight negative shift in $ZnCl_2$ (-2.2 °C) (Fig 2). Simultaneously we compared the effect of these ions on the stability of NP-exo LCMV (Fig 2). The Tm value for NP-exo LCMV without metal ions is 50.6 °C and increases in the presence of $MnCl_2$ (+13.6°C), $MgCl_2$ (+6 °C), $CaCl_2$ (+7.67 °C) but decreases with $ZnCl_2$ (-10.3 °C). These results indicate that the ion stabilization pattern for each ExoN is unique nevertheless, a similar stabilization trend is observed with $MnCl_2$ inducing highest

stability in all ExoNs. It is also worth noting that $CaCl_2$ which inhibits the 3'-5' ExoN activity is a better stabilizer than $MgCl_2$.

Our results show that stability and activity are uncoupled : lowering the energy of the domain is not key for activation. Rather the nature of the ion plays a key role : the small radius and higher coordination of Mn^{2+} over Mg^{2+} allow a higher number of water molecules available for being activated for the nucleophilic attack. On the contrary, Ca^{2+} with a larger radius slightly deforms the catalytic site [43] and increases the distances with the substrate, thus impairing the reaction.

NP-exo MOPV catalytic residues compared to NP-exo LCMV.

We mutated each catalytic residue to alanine in order to assess their respective contribution in the conserved DEDDh catalytic motif, and tested them for ExoN activity. For the NP-exo MOPV mutants D390A, E392A and D534A, the 3'-5' ExoN activity is completely abolished whereas D467A and H529A are still able to slowly excise up to two nucleotides. For the NP-exo LCMV mutants, a slightly different result is observed. D382A and E384A show a complete loss of activity, D459A excises two nucleotides but more efficiently than D467A of NP-exo MOPV as judged by the diminution of the 22 nts band-product. The H517A also shows residual activity while the D522A is able to degrade almost the total amount of 22 nt dsRNA up to 20/19 nts (Fig 1A). We compared the efficacy of cleavage between the wild type NP-exo MOPV and NP-exo LCMV to their corresponding mutants D467A and D459A respectively. Our kinetic experiment indicates that the initial excision rate of NP-exo MOPV and NP-exo LCMV wild types are similar, the rate of D459A of LCMV decreases to about half that of the wild-type, and that of MOPV D467A is significantly affected (S3 Fig).

NP-exo MOPV $_{ds}$RNA substrate specificity.

In order to investigate the substrate requirement for NP-exo MOPV, and NP-exo LCMV , we tested their activities on different RNA substrates HP4, A30 (poly A) and LE19. All these single stranded RNA ($_{ss}$RNA) forms several types of secondary structures RNA, which were predicted using Mfold server [59] (S2A Fig). The ExoN assay confirms and extends findings shown in Fig 1, *i.e* that NP-exo MOPV and NP-exo LCMV cleave RNA substrates whose 3' ends are engaged into a double stranded structure (Fig 3), consistent with a strict specific double stranded RNA requirement. It is particularly striking in the case of LE19 : at time 0, we observed the 3 species of secondary structures (migration for type A : 19 , B: 18 and C : 17 nucleotides respectively) and with time the top band-product disappears to the profit of an RNA of 17 nucleotides. We observed that NP-exo seems to be partly active on small secondary structure $_{ds}$RNA but is inactive on $_{ss}$RNA (Fig 3).

As the NP-exo MOPV presents similar *in vitro* behavior to other Arenavirus NP-exo, we conclude that the ExoN activity *per se* is not responsible for immune suppression, and that the latter is mediated by elements embedded in the domain itself. It was thus of interest to better characterize the substrate specificity of the NP-exo in order to disclose its role in arenavirus replication.

NP-exo is able to excise a $_{ds}$RNA 3'-end mismatch.

We measured NP-exo MOPV and NP-exo LCMV's ability to cleave different $_{ds}$RNA substrates. Because the key enzyme in the innate immune response; the protein kinase RNA-activated (PKR); is induced by the presence of $_{ds}$RNA, we made use of a perfectly annealed $_{ds}$RNA, as well as several potential RNA substrates such as those mimicking an erroneous replication product with one, two or three mismatched nucleotides at the 3'-end. To that end, a 40-mer RNA

template (RT1) blocked in 3'-end with a phosphate group was annealed to a radiolabeled RNA carrying zero (RL2*) or one (RL3*), two (RL4*) or three (RL5*) non-complementary nucleotides at its 3'-end as shown in Fig 4A. Fig 4B shows that both enzymes are strict $_{ds}$RNA ExoNs, with the interesting specific ability to digest substrates carrying a single 3'-terminal mismatch (RL3*/RT1). Quantification of total product (Fig 4C) shows a comparable hydrolytic activity between the perfectly annealed $_{ds}$RNA and a single 3'-terminal mismatch. The cleavage efficiency, however, drastically drops with the number of unpaired bases at the 3'-end.

The arenavirus NP-exo domain is structurally and functionally similar to the Coronavirus RNA 3'-mismatch excising ExoN.

The overall fold of NP-exo MOPV is homologous to that of the other arenavirus ExoNs [43]. Structural comparison reveals that the structure of NP-exo MOPV is very similar to that of LASV, LCMV and Tacaribe virus (TCRV) structures with overall r.m.s.d of ~1 Å or less, while the residues of the catalytic site are perfectly superimposed. Indeed, the four conserved catalytic residues (D390 E392 D467 H529 D534) from NP-exo MOPV are located at virtually identical positions as those of the other three ExoNs with only minor differences in their orientations. The Zn coordinating residues (E400, C507, H510 and C530) which are highly conserved in arenaviruses are also oriented in an identical manner in all four structures.

A fold similarity search retrieved three ExoN of various origin, namely *Arenaviridae*, *Coronaviridae*, and a human histone mRNA 3'-ExoNs (S4A Fig). Not only the catalytic core of all these enzymes is conserved (S4B Fig), but also they all possess the ability to remove few unpaired nucleotides in the 3'-to-5' direction. We analyzed comparatively the NP-exo MOPV structure and the nsp14 SARS-CoV protein (Fig 5) which also possesses a 3'-exoribonuclease activity able to excise 3'-end mismatch on $_{ds}$RNA [47]. The comparison of their topology and of their active site

shows that secondary structure elements belonging to the catalytic core are arranged in a similar manner. Our results suggest a common origin of the *Coronaviridae* Nsp14 and *Arenaviridae* NP ExoNs.

The arenavirus NP-exo domain affects viral replication but is not involved in genome stability.

To assess the possible role of the NP-exo activity in viral replication and/or genome stability, we passaged iteratively 10 times in Vero E6 cells at a MOI of 0.01 a NP-exo defective virus (NP-exo(-))carrying the D390A/G393A mutants as well as a NP-exo WT recombinant MOPV. We first quantified both the infectious titers (Fig 6A, left axis) and the NP RNA viral loads (Fig 6A, right axis) of the cell culture supernatants. Our results showed that the infectious viral titers of both viruses followed a parallel trend, the NP-exo(-) always presenting a 40 (minimum, passage 4) to 190 (maximum, passage 6) fold decrease in titer compared to the NP-exo WT MOPV. From passages 1 to 5/6, infectious titers continuously decreased (down to a 5 fold for the WT and down a 90 fold for the mutant compared to passage 1) before a rebound from passage 6 to 8/9 to titers similar to those of passage 2 followed by another general decrease at passage 10. The viral loads of NP-exo WT and NP-exo(-) MOPV described the same trends as the infectious viral titers albeit with less pronounced variations. The viral load for the WT virus remained stable along the passages with a maximum 3 fold difference while the NP-exo(-) virus had a maximum 13 fold difference.

We also calculated the RNA/FFU ratio for both viruses (Fig 6B). On average, the NP-exo WT and NP-exo mutant viruses respectively presented one infectious particle for 3600 and 23000 NP RNA copies, respectively. Interestingly, the maximum ratio was reached at passage 5 for both viruses with 1 FFU for 11300 copies for the WT NP-exo and 1 FFU for 119600 copies for the NP-exo(-). Therefore, the suppression of the NP-exo activity of MOPV promoted both a reduction of the infectious titer and an increased amount of non-infectious material released from infected cells.

We next investigated the genomic stability of these two viruses at passage 1 and 10 through deep sequencing analysis. We almost reached a complete coverage of the MOPV genomes except for the 5' and 3' end and most of the intergenic region of both segments. The tandem repeated and complementary sequences promote strong secondary structures in the intergenic regions and may explain the lack of reads observed for this region for both viruses.

The presence of WT NP sequences detected at passage one for both viruses likely originated from the plasmid expressing the WT NP ORF used for rescuing the virus (data not shown). To make sure our results matched a standard threshold usually observed with the presence of an internal control of sequencing, we considerate a 5% cutoff as a significant read percentage for the effective presence of a mutation (minimum mean coverage of 2636 reads for the L segment of the NP-exo(-) virus and maximum mean coverage of 12610 reads for the S segment of the NP-exo WT virus). As shown in Table 1 & S4, mutations targeting either the ORFs or the UTR/IGR regions are already present in both segments of the NP-exo WT and NP-exo(-) viruses (2.90 and 2.15 mutations/kb respectively) as early as passage one in VeroE6 cells after the virus rescue in BHKT7 cells. The overall mutation rate slightly increases comparatively at passage ten with 3.93 mutations/kb for the NPexo WT virus and 3.36 mutations/kb for the NP-exo(-) virus. Theses results indicate that NP ExoNs does not affect the overall genome stability but affects the viral replication.

The arenavirus NP-exo domain is active on its own genome.

We observe that the overall mutation rate is stable between NP-exo WT and NP-exo(-) MOPV, yet we also notice that the frequency of these mutations has changed. We observe at passage 10 a comparable number of mutations along the S segment but a decrease of ~ 22 % on the L segment of the mutant together with an increase of their occurrence frequencies. For both, these mutations appears along the entire L segment at an average frequency of ~ 10.1 % (comprised between 5 to 24

%) for the WT and of ~ 16.6 % (comprised between 5 to 93 %) for the mutant, in particular the substitution of C to T. While for the S segment mutations appear along the entire for the WT and clustered for the mutant at respective frequencies of 14.6 % and 19.5 %.

Among all mutations recorded, only a few were present for either both viruses and/or at the two different passages. Indeed, three mutations in the S segment and one mutation in the L segment are present for both viruses at passages one and ten and likely represent stable quasi-species (Table S4, and Table 1 yellow highlight).

Three mutations in the L segment are commonly found for the two viruses only at passage 10 (Table 1, orange highlight). Interestingly, three non-synonymous mutations in the L-polymerase ORF (S184L, S1021P and L1477S, Table 1, red highlight) became majority for the NP-exo(-) virus at passage 10.

To ascertain the trend observed in our genomic sequencing data, we investigated the natural occurrence of theses mutations in *Mammarenavirus* (MAMV) using bioinformatics. The pre-supposed being that if these mutations appear randomly they should be significantly (> 5 %) represented in the general population of MAMV and LASV.

From the three subsets of sequences generated; *i.e* MAMV, LASV and MOPV; we observed that the three mutations S184L, S1021P and L1477S appeared in conserved regions in all three subsets, that none of the three mutants were reported in MOPV subset and finally that the three amino acid are subject to diverse selective pressure (Fig 7). Indeed, serine at the position 184 represents the majority of the observed amino acid variants while the specific mutation S184L represents only 1 % of the total observed sequences in the LASV or MAMV subsets. This observation indicates that the mutation is viable but most likely costly to be maintained by the virus. On the other hand, at position 1021, the serine observed in MOPV subset does not represent the majority of the observed amino acid in the other subsets, the proline is by far the most frequent amino acids found (Fig 7). In

LASV, the serine subset represents only 3% of the observed amino acids at this position while 10% in the MAMV subset (Fig 7). This observation indicates that this position in MOPV is an oddity compared to the others. It seems that the natural tendency in the L protein is to have a proline rather than a serine at this position. The fact that we observe that particular reversion in the NP-Exo(-) could indicate that for L MOPV there is a constraint at this particular position. Finally, at position 1477, the amino acid found at this position for the three subsets is a leucine (Fig 7), indicating that, that particular position is under a high selective pressure. The mutation L1477S was never observed in any subsets, this mutation can be interpreted as unlikely and therefore considered as direct consequence of the NP-Exo(-).

Our results show that compared to the WT virus, the abrogation of the NP-exo activity did not increase the mutation rate found in the MOPV genomic sequences present in the cell culture supernatant, but the emergence of the three mutants of rare occurrence are the direct consequence of the NP-Exo(-), which have relaxed the control over certain position implying a direct effect of the MOPV exonuclease on its own genomic RNA.

Discussion

The paradigm of *Arenaviridae* NP ExoN states that it is involved in innate immunity suppression [37,60–62], through degradation of $_{ds}$RNAs which would otherwise stimulate the innate immunity response. Several reports have demonstrated that NP is responsible for the degradation of these $_{ds}$RNAs using the 3'-5' ExoN located at its C-terminus [25,32,35,63]. This ExoN comprises a DEDDh catalytic motif that is completely conserved across the *Arenaviridae* [35] implying this activity may be a general feature of arenavirus NPs. The ExoN domain is conserved within the family regardless of both the virus pathogenic potential and its ability to suppress efficiently type I IFN, as previously reported for TCRV and MOPV [42,60,64]. MOPV is the closest counterpart of

LASV and presents a 73% NP sequence identity with LASV. During LASV infections, the virus targets mainly macrophages (MP) and dendritic (DC) cells [65], and infections are characterized by high viremia and generalized immune suppression supposedly due to innate immune inhibition by the ExoN domain. Both MOPV and LASV induces strong type I IFN responses in MP and moderately in DC, but contrarily to LASV which abrogates this response, MOPV does not [42,64].

Our functional study demonstrates that the ExoN structure, substrate specificity, and mechanism is indeed conserved across the family. It is also clear from the structure-ion analysis [43], that toying with the catalytic ion leads to slight structural changes which impact dramatically the activity. Although NP-exo MOPV, NP-exo LCMV have similar cleavage patterns, mutation analysis of the DEDDh motif reveals that the exact residues critical for 3'-5' ExoN vary between both domains. For NP-exo MOPV, D390A, E392A and D534A (D389A, E391A and D533A LASV equivalents) completely abolishes 3'-5' ExoN activity consistent with results from *in vitro* studies on LASV [35], while D467A and H529A (D466A and H529A LASV equivalents) retains some residual activity (see below). For NP-exo LCMV, a previous study by Martínez-Sobrido and collaborators [61], correlated innate immunity suppression to ExoN mutants, postulating a direct involvement of the ExoN activity. We observed that mutant D382A completely loses ExoN activity consistently with results from reverse genetic studies [61]. A noticeable difference concern the mutant E384A, that was shown to have no effect and be dispensable for ExoN activity [61], is rather shown critical in our *in vitro* study and consistent with the structural data as E384 (equivalent to MOPV E392) is involved in binding one of the catalytic ion (S4 Fig). Under our conditions, D459A and H517A still retains their ability to cleave two nucleotides meanwhile D522A shows a significant activity leading to the removal of two to three nucleotides. Theses latter three mutants were not reported before but the analysis of the structure of NP-exo MOPV confirms that major features such as fold, and the two ion binding sites (catalytic and structural) are conserved within

the *Arenaviridae* [25,32,35,36,63]. Residues D390, E392, D534 of NP-exo MOPV directly coordinate the catalytic ion. Mutation of these residues logically alter ion binding and thus leads to complete loss of catalytic activity. The residual activity observed for D522A of NP-exo LCMV is rather difficult to explain as the two structures present no clear differences in the ion binding mode. The only noticeable difference is about the hydrophobic environment that may compensate the faulty metal-binding site in the case of NP-exo LCMV. The residual activity observed for D467 (D459 of LCMV) is rather difficult to explain as the two structures present no clear differences, yet that residue is very likely involved in the cleavage mechanism. Indeed, the kinetic experiments comparing the WT NP-exo MOPV and NP-exo LCMV to corresponding mutants show that the first event of the hydrolysis is comparable between NP-exo MOPV and NP-exo LCMV, while mutation of the aspartate reduces drastically the hydrolysis kinetics for NP-exo MOPV but only moderately for NP-exo LCMV (S3 Fig). These differences suggest that the aspartate (respectively D467, D459) is involved in the structural set-up of the active site for positioning the ion responsible for the nucleophilic attack. The general mechanism for RNA hydrolysis is a two metal ion mechanism described by Steitz and Steitz [66]. It involves metal A and B positioned ~4 Å apart each other and across the target phosphodiester bond. Metal ion A facilitates the formation of the attacking nucleophile. This is followed by the formation of a penta-covalent intermediate which is stabilized by both metal ions. Metal ion B then eases the exit of the leaving group. With the help of the LASV structures of Jiang and collaborator [36], we made an attempt to reconstitute a model of the general mechanism for RNA hydrolysis (S5A Fig). In NP-exo MOPV structure (and all the others) only the metal B is visible. The site receiving the other catalytic metal A is partly created with interaction of the RNA and residues D390 and D467 (S5B Fig). The interaction between the ion in position A and D467 is mediated through a water molecule. Therefore, this might explain why this mutant retained a partial residual activity.

As it was shown for TCRV, the ExoN domain of MOPV *in vitro* is endowed with full ExoN activity and obeys to the same structural and energetic constraints as those of other *Arenaviridae* ExoNs [36,43]. Therefore MOPV ExoN activity alone is not *per se* responsible for the differences in innate immunity suppression between MOPV and LASV. Rather, the presence of the ExoN activity may serve other purposes in the viral life cycle, which might be connected directly or indirectly to innate immunity.

In particular, previous studies on LCMV and PICV suggested that altering the NP ExoN also impacts replication, irrespective to the IFN status of the host cell [61,67]. The structural relatedness with the Coronavirus ExoN and its implication in viral replication prompted us to investigate to which extend the arenavirus ExoN domain is able to excise unpaired nucleotides. Our enzyme activity assays demonstrate that NP-exo MOPV and NP-exo LCMV can efficiently and selectively cleave a $_{ds}$RNA mimicking an erroneous replication product carrying one 3'-mismatched nucleotide (Fig 4). Our analysis confirms that despite additional inserted structural elements, the two domains belong to the same Ribonuclease H-like superfamily. In the case of *Coronaviridae,* several studies have pointed to a main role of the ExoN domain of nsp14 in RNA proofreading [47–50] to maintain genome stability. Structural comparison between ExoN domain of nsp14 and MOPV shows conservation of active site and main fold (Fig 5) suggesting that they have a distant but common origin. Recent work by Becares and colleagues have shown that nsp14 of Coronavirus is also involved in innate immunity modulation [68]. Therefore, these data show that at least in *Coronaviridae* the 3'-5' ExoN activity is not exclusively assigned to a specific role but is involved in different aspect of the viral life cycle. Our study present clear evidence that much like the coronavirus nsp14 [47], the *Arenaviridae* NP ExoN excises a 3'-end mismatch $_{ds}$RNA *in vitro*, and based on previous report that this activity is directly connected to RNA replication [61,67].

From our data, the MOPV polymerase exhibits an average error rate estimated around 3

482 mutations / kb. This means that the polymerase was able to incorporate a mismatch and then
483 elongate it. The error rate does not change between the WT and the mutant, which is consistent with
484 the fact that we did not altered the polymerase. For both, these mutations appears along the entire L
485 segment at an average frequency of ~10.1 % (comprised between 5 to 24 %) for the WT and of
486 ~16.6 % (comprised between 5 to 93 %) for the mutant. The fact that unlikely mutants have become
487 prevalent, as observed at passage 10, reflect that the control over certain type of mutation have been
488 abolished, thus implicating that ExoN is active on its own genomic RNA. In this study, it is not the
489 particular set of mutations that is relevant but rather that a set of unlikely mutations have emerged.
490 The bias inferred by impairment of the ExoN, together with the biochemistry presented here is
491 consistent with the idea that ExoN is involved in a mismatch excision system.

492 Although the presence of mismatch excision system is logically associated to very large
493 genomes (~30 kb) in *Coronaviridae*, the presence of such activity, and potentially such RNA repair
494 system, in *Arenaviridae* of intermediate genome size (~11 kb) remains puzzling. Our results shows
495 a clear diminution of the viral titer for viruses depleted of ExoN activity, but no clear evidence of a
496 drastic increase of mutation in the genome that would lead to catastrophic event. Then what is
497 happening in these mutated viruses? One tentative explanation could be the ExoN is involved in : *i*)
498 checking and maintaining the sequence integrity of the conserved genomic region at its extremities,
499 and/or *ii*) the structural integrity of the Intergenic Region (IGR). Indeed, both regions have been
500 previously reported as being critical for viral fitness: *i*) The conserved region (19 nucleotides)
501 exhibit high degree of sequence conservation at the 3'-termini and is complementary to the 5' end of
502 the genome (for review [26]). This sequence serves as a selective docking platform for the
503 polymerase [69] for which 3'-end binds with high affinity and in a sequence specific manner [70].
504 *ii*) Similarly, alteration of the IGR structure leads to reduce efficient transcription termination and
505 viral assembly [71,72]. In such hypothesis, the impairment of the NP-exo activity leads to a

scenario in which the polymerase is able to incorporate a mismatch but is unable to elongate it, leading to a decrease of suitable genomic material to package, therefore without the ExoN control the number of functional RNP would be reduced and consistent with the loss of viral fitness observed here and else [61,67]. Therefore we propose that the Arenavirus ExoN is involved in a "limited proof-reading" mechanism driven by structural constraints rather than genomic stability. Another observation that concurs to the "limited proof-reading" mechanism is the difference of Ribavirin efficiency on *Arenaviridae and Coronaviridae.* Ribavirin is the only drug so far administered on large scale and having demonstrated a decrease of mortality rates up to 5%, if administered within the first 6 days of arenaviral illness [73]. On the other hand, Ribavirin is ineffective against coronaviruses [74,75], as nsp14 ExoN domain excises the nucleotide analogue [51]. It is likely, that for *Arenaviridae,* the ExoN activity involved in a "limited proof-reading" mechanism remains as a trace of its past common ancestor with *Coronaviridae*. The critical problem of genomic stability being solved, either by the conservation of the "original" function of the ExoN for *Coronaviridae*, or by genome segmentation for *Arenaviridae*.

As a conclusion we have shown that the MOPV ExoN is fully functional, behaving like other Arenaviral ExoN on $_{ds}$RNA. We have demonstrated that Arenaviral ExoN are able to excise an RNA mismatch, and that is active on its own genomic RNA like its counterpart in *Coronaviridae*. Under the conditions used here, abrogation of ExoN activity does not impact genomic stability significantly. Our results suggest that the *Arenaviridae* RNA ExoN, like that of *Coronaviridae*, is at a crossroad between replication efficiency and innate immunity evasion in the infected cell.

Acknowledgments

This work was supported by ANR grants ArenaBunya-L (ANR-11-BSV8-0019), the Centre National de la Recherche Scientifique (CNRS), the Fondation Infection Mediterrannée, and the French Infrastructure for Integrated Structural Biology (FRISBI) ANR-10-INSB-05-01. The authors also thank Dr. Barbara Selisko for her help and useful discussion and Julie Lichière for her contribution in the experiments.

535 ## References

1. Buchmeier MJ, de la Torre J-C, Peters CJ, Torre JD. Arenaviridae: The Viruses and Their Replication. In: Knipe DM, Howley PM, editors. Fields Virology. 5th ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2007. pp. 1791–1827.

2. Mets MB, Barton LL, Khan AS, Ksiazek TG. Lymphocytic choriomeningitis virus: An underdiagnosed cause of congenital chorioretinitis. Am J Ophthalmol. 2000;130: 209–215. doi:10.1016/S0002-9394(00)00570-5

3. Brézin AP, Thulliez P, Cisneros B, Mets MB, Saron MF. Lymphocytic choriomeningitis virus chorioretinitis mimicking ocular toxoplasmosis in two otherwise normal children. Am J Ophthalmol. 2000;130: 245–247. doi:10.1016/S0002-9394(00)00563-8

4. Barton LL, Mets MB, Beauchamp CL. Lymphocytic choriomeningitis virus: Emerging fetal teratogen. Am J Obstet Gynecol. 2002;187: 1715–1716. doi:10.1067/mob.2002.126297

5. Barton LL, Peters CJ, Ksiazek TG. Lymphocytic choriomeningitis virus: an unrecognized teratogenic pathogen. Emerg Infect Dis. 1995;1: 152–153.

6. Jamieson DJ, Kourtis AP, Bell M, Rasmussen SA. Lymphocytic choriomeningitis virus: An emerging obstetric pathogen? Am J Obstet Gynecol. 2006;194: 1532–1536. doi:10.1016/j.ajog.2005.11.040

7. Bowen MD, Peters CJ, Nichol ST. The phylogeny of New World (Tacaribe complex) arenaviruses. Virology. 1996;219: 285–290. doi:10.1006/viro.1996.0248

8. Briese T, Paweska JT, McMullan LK, Hutchison SK, Street C, Palacios G, et al. Genetic detection and characterization of Lujo virus, a new hemorrhagic fever-associated arenavirus

from southern Africa. Buchmeier MJ, editor. PLoS Pathog. 2009;5: e1000455–e1000455. doi:10.1371/journal.ppat.1000455

9. Peterson a T, Moses LM, Bausch DG. Mapping transmission risk of lassa Fever in west Africa: the importance of quality control, sampling bias, and error weighting. PloS One. 2014;9: e100711–e100711. doi:10.1371/journal.pone.0100711

10. Leparc-Goffart I, Emonet SF. [An update on Lassa virus]. Médecine Trop Rev Corps Santé Colon. 2011;71: 541–5.

11. Yun NE, Walker DH. Pathogenesis of Lassa Fever. Viruses. 2012;4: 2031–2048. doi:10.3390/v4102031

12. Mofolorunsho KC. Outbreak of lassa fever in Nigeria: measures for prevention and control. Pan Afr Med J. 2016;8688: 2–4. doi:10.11604/pamj.2016.23.210.8923

13. Günther S, Lenz O. Lassa Virus. Crit Rev Clin Lab Sci. 2004;41: 339–390. doi:10.1080/10408360490497456

14. Centers for Disease Control and Prevention. CDC twenty four Centers for Disease Control and Prevention. Lassa Fever [Internet]. Available: https://www.cdc.gov/vhf/lassa/

15. Yun NE, Ronca S, Tamura A, Koma T, Seregin A V., Dineley KT, et al. Animal Model of Sensorineural Hearing Loss Associated with Lassa Virus Infection. Ross SR, editor. J Virol. 2015;90: 2920–7. doi:10.1128/JVI.02948-15

16. WHO Africa. WHO moves to contain Nigeria’s Lassa fever outbreak. In: Disease Outbreak News [Internet]. 2018 [cited 13 Mar 2018]. Available: http://www.afro.who.int/news/who-moves-contain-nigerias-lassa-fever-outbreak

17. W.H.O. Lassa Fever – Nigeria. In: Disease Outbreak News [Internet]. 2016 [cited 8 Aug 2016]. Available: http://who.int/csr/don/27-may-2016-lassa-fever-nigeria/en/

18. W.H.O. Lassa Fever – Benin. In: Disease Outbreak News [Internet]. 2016 [cited 8 Aug 2016]. Available: http://www.who.int/csr/don/13-june-2016-lassa-fever-benin/en/

19. Clegg JC. Influence of climate change on the incidence and impact of arenavirus diseases: A speculative assessment. Clin Microbiol Infect. 2009;15: 504–509. doi:10.1111/j.1469-0691.2009.02847.x

20. Fisher-Hoch SP, Tomori O, Nasidi a, Perez-Oronoz GI, Fakile Y, Hutwagner L, et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ. 1995;311: 857–9.

21. Sullivan BM, Teijaro JR, de la Torre JC, Oldstone MBA. Early Virus-Host Interactions Dictate the Course of a Persistent Infection. Feng P, editor. PLoS Pathog. 2015;11: e1004588–e1004588. doi:10.1371/journal.ppat.1004588

22. Huang C, Kolokoltsova OA, Yun NE, Seregin AV, Ronca S, Koma T, et al. Highly Pathogenic New World and Old World Human Arenaviruses Induce Distinct Interferon Responses in Human Cells. J Virol. 2015;89: 7079–88. doi:10.1128/JVI.00526-15

23. Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, et al. Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection. Science. 2013;340: 202–207. doi:10.1126/science.1235208

24. Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KCF, Welch M, et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science. 2013;340: 207–11.

doi:10.1126/science.1235214

25. Qi X, Lan S, Wang W, Schelde LM, Dong H, Wallat GD, et al. Cap binding and immune evasion revealed by Lassa nucleoprotein structure. Nature. 2010;468: 779–783. doi:10.1038/nature09605

26. Ferron F, Weber F, de la Torre JC, Reguera J. Transcription and replication mechanisms of Bunyaviridae and Arenaviridae L proteins. Virus Res. 2017; 1–17. doi:10.1016/j.virusres.2017.01.018

27. Cornu TI, de la Torre JC. RING finger Z protein of lymphocytic choriomeningitis virus (LCMV) inhibits transcription and RNA replication of an LCMV S-segment minigenome. J Virol. 2001;75: 9415–26. doi:10.1128/JVI.75.19.9415-9426.2001

28. Perez M, Greenwald DL, de la Torre JC. Myristoylation of the RING finger Z protein is essential for arenavirus budding. J Virol. 2004;78: 11443–11448.

29. Hastie KM, Zandonatti M, Liu T, Li S, Woods VL, Saphire EO. Crystal Structure of the Oligomeric Form of Lassa Virus Matrix Protein Z. J Virol. 2016;90: 4556–62. doi:10.1128/JVI.02896-15

30. Burri DJ, da Palma JR, Kunz S, Pasquato A. Envelope glycoprotein of arenaviruses. Viruses. 2012;4: 2162–81. doi:10.3390/v4102162

31. Hastie KM, Igonet S, Sullivan BM, Legrand P, Zandonatti MA, Robinson JE, et al. Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV. Nat Struct Mol Biol. 2016;23: 513–521. doi:10.1038/nsmb.3210

32. Brunotte L, Kerber R, Shang W, Hauer F, Hass M, Gabriel M, et al. Structure of the Lassa

virus nucleoprotein revealed by X-ray crystallography, small-angle X-ray scattering, and electron microscopy. J Biol Chem. 2011;286: 38748–56. doi:10.1074/jbc.M111.278838

33. Hastie KM, Liu T, Li S, King LB, Ngo N, Zandonatti M a, et al. Crystal structure of the Lassa virus nucleoprotein-RNA complex reveals a gating mechanism for RNA binding. Proc Natl Acad Sci U S A. 2011;108: 19365–70. doi:10.1073/pnas.1108515108

34. Pinschewer DD, Perez M, de la Torre JC. Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J Virol. 2003;77: 3882–3887.

35. Hastie KM, Kimberlin CR, Zandonatti MA, MacRae IJ, Saphire EO. Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3’ to 5’ exonuclease activity essential for immune suppression. Proc Natl Acad Sci U S A. 2011;108: 2396–401. doi:10.1073/pnas.1016404108

36. Jiang X, Huang Q, Wang W, Dong H, Ly H, Liang Y, et al. Structures of arenaviral nucleoproteins with triphosphate dsRNA reveal a unique mechanism of immune suppression. J Biol Chem. 2013;288: 16949–59. doi:10.1074/jbc.M112.420521

37. Ortiz-Riaño E, Cheng BYH, de la Torre JC, Martínez-Sobrido L. The C-Terminal Region of Lymphocytic Choriomeningitis Virus Nucleoprotein Contains Distinct and Segregable Functional Domains Involved in NP-Z Interaction and Counteraction of the Type I Interferon Response. J Virol. 2011;85: 13038–48. doi:10.1128/JVI.05834-11

38. Yoneyama M, Onomoto K, Fujita T. Cytoplasmic recognition of RNA. Adv Drug Deliv Rev. 2008;60: 841–6. doi:10.1016/j.addr.2007.12.001

39. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5: 730–7. doi:10.1038/ni1087

40. Bowen MD, Rollin PE, Ksiazek TG, Hustad HL, Bausch DG, Demby AH, et al. Genetic Diversity among Lassa Virus Strains. J Virol. 2000;74: 6992–7004. doi:10.1128/JVI.74.15.6992-7004.2000

41. Lukashevich IS, Maryankova R, Vladyko a S, Nashkevich N, Koleda S, Djavani M, et al. Lassa and Mopeia virus replication in human monocytes/macrophages and in endothelial cells: different effects on IL-8 and TNF-alpha gene expression. J Med Virol. 1999;59: 552–560. doi:10.1002/(SICI)1096-9071(199912)59:4<552::AID-JMV21>3.0.CO;2-A

42. Pannetier D, Faure C, Georges-Courbot M-C, Deubel V, Baize S. Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection. J Virol. 2004;78: 10516–24. doi:10.1128/JVI.78.19.10516-10524.2004

43. Yekwa E, Khourieh J, Canard B, Papageorgiou N, Ferron F. Activity inhibition and crystal polymorphism induced by active-site metal swapping. Acta Crystallogr Sect Struct Biol. 2017;73: 641–649. doi:10.1107/S205979831700866X

44. Carnec X, Mateo M, Page A, Reynard S, Hortion J, Picard C, et al. A Vaccine Platform against Arenaviruses Based on a Recombinant Hyperattenuated Mopeia Virus Expressing Heterologous Glycoproteins. J Virol. 2018;92: 1–17. doi:10.1128/JVI.02230-17

45. Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR. High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J Virol. 2007;81: 12135–44. doi:10.1128/JVI.01296-07

46. Minskaia E, Hertzig T, Gorbalenya AE, Campanacci V, Cambillau C, Canard B, et al. Discovery of an RNA virus 3'->5' exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci U S A. 2006;103: 5108–13. doi:10.1073/pnas.0508200103

47. Bouvet M, Imbert I, Subissi L, Gluais L, Canard B, Decroly E. RNA 3'-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc Natl Acad Sci U S A. 2012;109: 9372–7. doi:10.1073/pnas.1201130109

48. Eckerle LD, Becker MM, Halpin RA, Li K, Venter E, Lu X, et al. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. Emerman M, editor. PLoS Pathog. 2010;6: e1000896–e1000896. doi:10.1371/journal.ppat.1000896

49. Denison MR, Graham RL, Donaldson EF, Eckerle LD, Baric RS. Coronaviruses: An RNA proofreading machine regulates replication fidelity and diversity. RNA Biol. 2011;8: 270–279. doi:10.4161/rna.8.2.15013

50. Subissi L, Imbert I, Ferron F, Collet A, Coutard B, Decroly E, et al. SARS-CoV ORF1b-encoded nonstructural proteins 12-16: Replicative enzymes as antiviral targets. Antiviral Res. 2014;101: 122–30. doi:10.1016/j.antiviral.2013.11.006

51. Ferron F, Subissi L, Silveira De Morais AT, Le NTT, Sevajol M, Gluais L, et al. Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA. Proc Natl Acad Sci U S A. 2018;115: E162–E171. doi:10.1073/pnas.1718806115

52. Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr D Biol Crystallogr. 2004;60: 2256–

2268. doi:10.1107/S0907444904026460

53. Armougom F, Moretti S, Poirot O, Audic S, Dumas P, Schaeli B, et al. Expresso: Automatic incorporation of structural information in multiple sequence alignments using 3D-Coffee. Nucleic Acids Res. 2006;34: 604–608. doi:10.1093/nar/gkl092

54. Gouet P, Robert X, Courcelle E. ESPript/ENDscript: Extracting and rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res. 2003;31: 3320–3. doi:10.1093/nar/gkg556

55. Crooks G, Hon G, Chandonia J, Brenner S. WebLogo: a sequence logo generator. Genome Res. 2004;14: 1188–1190. doi:10.1101/gr.849004.1

56. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera - A visualization system for exploratory research and analysis. J Comput Chem. 2004;25: 1605–1612. doi:10.1002/jcc.20084

57. Brandt BW, Feenstra KA, Heringa J. Multi-Harmony: detecting functional specificity from sequence alignment. Nucleic Acids Res. 2010;38: W35-40. doi:10.1093/nar/gkq415

58. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32: 1792–7. doi:10.1093/nar/gkh340

59. Zuker M. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res. 2003;31: 3406–15.

60. Martínez-Sobrido L, Giannakas P, Cubitt B, García-Sastre A, de la Torre JC. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J Virol. 2007;81: 12696–703. doi:10.1128/JVI.00882-07

61. Martínez-Sobrido L, Emonet S, Giannakas P, Cubitt B, García-Sastre A, de la Torre JC. Identification of amino acid residues critical for the anti-interferon activity of the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol. 2009;83: 11330–11340. doi:10.1128/JVI.00763-09

62. Reynard S, Russier M, Fizet A, Carnec X, Baize S. Exonuclease domain of the Lassa virus nucleoprotein is critical to avoid RIG-I signaling and to inhibit the innate immune response. J Virol. 2014;88: 13923–7. doi:10.1128/JVI.01923-14

63. Hastie KM, King LB, Zandonatti MA, Saphire EO. Structural basis for the dsRNA specificity of the Lassa virus NP exonuclease. PloS One. 2012;7: e44211. doi:10.1371/journal.pone.0044211

64. Pannetier D, Reynard S, Russier M, Journeaux A, Tordo N, Deubel V, et al. Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus. J Virol. 2011;85: 8293–306. doi:10.1128/JVI.02120-10

65. Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot M-C, Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol Baltim Md 1950. 2004;172: 2861–9.

66. Steitz T a, Steitz J a. A general two-metal-ion mechanism for catalytic RNA. Proc Natl Acad Sci U S A. 1993;90: 6498–6502. doi:10.1073/pnas.90.14.6498

67. Huang Q, Shao J, Lan S, Zhou Y, Xing J, Dong C, et al. In Vitro and In Vivo Characterizations of Pichinde Viral Nucleoprotein Exoribonuclease Functions. J Virol. 2015;89: 6595–6607. doi:10.1128/JVI.00009-15

68. Becares M, Pascual-Iglesias A, Nogales A, Sola I, Enjuanes L, Zuñiga S. Mutagenesis of Coronavirus nsp14 Reveals Its Potential Role in Modulation of the Innate Immune Response. J Virol. 2016;90: 5399–414. doi:10.1128/JVI.03259-15

69. Gerlach P, Malet H, Cusack S, Reguera J. Structural insights into bunyavirus replication and its regulation by the vRNA promoter. Cell. 2015;161: 1267–1279. doi:10.1016/j.cell.2015.05.006

70. Kranzusch PJ, Schenk AD, Rahmeh AA, Radoshitzky SR, Bavari S, Walz T, et al. Assembly of a functional Machupo virus polymerase complex. Proc Natl Acad Sci U S A. 2010; 1–6. doi:10.1073/pnas.1007152107

71. Pinschewer DD, Perez M, de la Torre JC. Dual role of the lymphocytic choriomeningitis virus intergenic region in transcription termination and virus propagation. J Virol. 2005;79: 4519–26. doi:10.1128/JVI.79.7.4519-4526.2005

72. Iwasaki M, Cubitt B, Sullivan BM, de la Torre JC. The High Degree of Sequence Plasticity of the Arenavirus Noncoding Intergenic Region (IGR) Enables the Use of a Nonviral Universal Synthetic IGR To Attenuate Arenaviruses. J Virol. 2016;90: 3187–97. doi:10.1128/JVI.03145-15

73. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314: 20–6. doi:10.1056/NEJM198601023140104

74. Stockman LJ, Bellamy R, Garner P. SARS: Systematic Review of Treatment Effects. Low D, editor. PLoS Med. 2006;3: e343–e343. doi:10.1371/journal.pmed.0030343

75. Al-Tawfiq JA, Memish ZA. Update on therapeutic options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Expert Rev Anti Infect Ther. 2017;15: 269–275. doi:10.1080/14787210.2017.1271712

536

Figure legends

Fig 1. Comparison of the ExoN activity of NP-exo MOPV and NP-exo LCMV. (A) Effect of divalent cations on ExoN activity of NP-exo MOPV and NP-exo LCMV. RNA HP4 was incubated with NP-exo MOPV or NP-exo LCMV for 0, 0.1, 5 and 30 minutes (min) in the presence of 5 mM Mg^{2+}, Mn^{2+}, Zn^{2+}, Ca^{2+}, or EDTA. Digestion products were separated on a 20 % denaturing PAGE and revealed by autoradiography. (B) Comparative mutational analysis of ExoN activity. The DEDDh residues were mutated to alanine. Equal amounts of wild type (WT) or mutants of NP-exo MOPV or NP-exo LCMV were incubated with HP4 for 0, 5 and 30 mins. Products were separated on denaturing PAGE and visualized by autoradiography. NC indicates the substrate without proteins. Sketch on the top of figure A illustrates the hairpin structure of HP4. On the side of each gel is presented the migration size ladder in nucleotides (nts).

Fig 2. Effect of divalent-Cation on thermal stability of NP-exo MOPV and NP-exo LCMV. Bar chart showing the shifts in melting temperatures of NP-exo MOPV and NP-exo LCMV measured in the presence of 5 mM of the indicated ions by TSA.

Fig 3. **Comparison of the substrate on the ExoN activity of NP-exo MOPV and NP-exo LCMV.** Comparative ExoN activity on three different RNA substrate ; A30 (ssRNA), LE19 (ssRNA forming three types of secondary structures), HP4 (stable RNA hairpin). Equal amounts of each RNA substrate were incubated with NP-exo MOPV or NP-exo LCMV for 0, 5, 30 minutes. Digestion products were analyzed as in Fig1. On the side of each gel is presented the migration size ladder in

nucleotides (nts). A star highlight the enrichment of the band corresponding of a RNA of 17 nts Type A RNA with degradation of 2 nucleotides.

Fig 4.Time course hydrolysis of paired and mismatched 3'-end nucleotide base pair by NP-exo MOPV and NP-exo LCMV. (A) Schematic representation of dsRNA mimicking a replication intermediate. RL2*/RT1, RL3*/RT1, RL4*/RT1 and RL5*/RT1 represent dsRNAs carrying either zero, one, two and three non-complementary nucleotides respectively at their 3'-ends. (B) Equal amounts of the dsRNA substrate (1,25 µM) listed above were incubated in the absence or presence of 0,25 µM of NP-exo MOPV or NP-exo LCMV at 37 °C for 1, 2, 5 and 10 min. 0 is negative control without proteins. A migration size ladder in nucleotides (nts) is presented on the side of the gel. Digestion products were analyzed on 20% denaturing PAGE and visualized by autoradiography. (C) Bar graph showing the total degradation product of substrate at various times. Total degradation products were quantified using phosphoimager FLA-3000 (Fuji) and graphs plotted using Graphpad. PRISM.

Fig 5. Comparison of the ExoN domains : nsp14 SARScoV and NP-exo MOPV. Topology diagrams of the (A) nsp14 SARScoV and (B) NP-exo MOPV. The 5 β-strands that constitute the central β-sheet are colored blue, pink, brown, yellow and green from the first to the fifth strand respectively. The 4th and 6th α-helices of the DEDD motif are colored purple and orange respectively. The uncolored spheres represent additional non-conserved secondary structures. The location of the catalytic residues are indicated with red spheres. Extra domain insertions for each ExoN are enclosed with in the large gray circles. The N and C terminals are indicated with the uncolored squares. The topology diagrams indicates a similar fold and a conservation of the catalytic core for both ExoNs. (C) Structural alignment of the active sites of nsp14 SARScoV and NP-exo MOPV. Color codes are same as in the topology diagrams except for secondary structures

colored cyan (NP-exo MOPV) or sandy brown (nsp14 SARScoV) which are not a part of the catalytic fold. The superposition shows that catalytic residues are located at virtually identical positions.

Fig. 6. Effect of inactivated ExoN viruses on viral fitness and genome stability. (A) Iterative passages of NP-exo WT and D390A/G393A recombinant MOPV in Vero E6 cells. *De novo* stocks of both viruses, from passage 1 to passage 10, were used to infect cells for 4 days with MOI 0.01. Samples of supernatants were collected for viral infectious titration and NP RNA copy quantification. Results for the left Y axis represent the infectious viral titers (FFU/mL) and results from the right Y axis represent the NP RNA load (NP RNA copies/mL) of the corresponding cell culture supernatants. (B) Ratio calculation for NP RNA copy load over infectious viral titer (RNA copies / FFU) for NP-exo WT and D390A/G393A recombinant MOPV for the ten passages considered in (A).

Fig. 7. Representation of statistical occurrence of an amino acid at specific position. Represented the WebLogo of the corresponding MOPV amino acids S184, S1021 L1477 in all Mammarenavirus, LASSV and MOPV sub set of sequences. The position of the residue of interest is indicated with a red star. Size of the residue is proportional to it probability of occurrence (0 – 1). For clarity, on the side of the WebLogo is the detailed the statistical occurrence of all amino acids found in the deposited sequences.

Supporting information

S1 Fig. Modular and organization of *Arenavidae'* NP. Schematic of the two domains organization of *Arenaviridae*' NP, with its corresponding domains structures. N-terminal domain corresponding to the nucleoprotein domain (PDB : 3T5N) and C-terminal domain corresponding to the ExoN domain (PDB : 3Q7C) of LASV. Each domain is represented in ribbon and colored following rainbow nomenclature from blue (N-terminus) to red (C-terminus). Flexible linker is represented as green line.

S2 Fig. Secondary structures adopted by RNA substrates used in the study. (A) These structures were predicted using Mfold server (http://unafold.rna.albany.edu/?q=mfoldand). The minimum free energy of each structure is indicated below it. RNA HP4 is a stable RNA hairpin. RNA LE19 presents 3 types of secondary structures. Type A : two double stranded nucleotides, type B : long hanging 5' and short hanging 3' extremities, type C : long 5' 3' Hanging extremities. RNA A30 long single stranded RNA without secondary structure. (B) Expected pattern of digestion based on a dsRNA 3'5' ExoN activity for each type of tested RNA.

S3 Fig. Kinetics of HP4 cleavage by NP-exo MOPV WT, its Mutant D467A, NP-exo LCMV WT or the corresponding mutant D459A. HP4 was incubated with equal concentration of NP-exo MOPV WT, D467A , NP-exo LCMV WT or D459A for 0, 2, 4, 6, 8, 10 and 15 mins. Reactions products were separated on 20 % denaturing PAGE and products revealed by autoradiography. RNA cleavage was then quantified from this data and plotted as the percentage of product formed with time.

S4 Fig. Structural alignment of 3'-5' ExoN : (A) Ribbon representation of the superposition of NP-exo Mopeia Virus (cyan pdb : 5LRP), nsp14 SARScoV Exo (beige pdb : 5C8S), NP-exo Lassa Virus (orange pdb : 4FVU), histone mRNA stem-loop by 3'-ExoN Homo Sapiens (green pdb 1ZBH). All structures were retrieved by PDBeFold (http://www.ebi.ac.uk/msd-srv/ssm), all similar sequences were discarded. Overall fold is similar; in caption a zoom of the active site shows a quasi perfect superimposition of the DEDD motif. Green spheres are in the zoom represent Mg ions. (B) Weblogo of the active site derived from the structural alignment. Structure and sequence comparison lead to conclude to a common origin of the ExoNs.

S5 Fig. A model of the mechanism of calcium inhibition of 3'-5' ExoN activity. (A) The dsRNA from LASV NP-C structure (PBD code:4GV9) modeled into the MOPV Nexo-Mg structure. MOPV-Mg represented as cartoon (Helices in orange, β-strands in green and loops in cyan) and the dsRNA is shown as a stick model. The green balls represent magnesium atom. (B) An enlarged view of the active indicating the model positions of ions during cleavage mechanism. Calcium substitution of the magnesium ion mediates inhibition of 3'-5' ExoN activity as a result of its atomic radius, binding flexibility and poor activation of water. Ca atom is represented in grey.

S1 Table. Primer sequences used for mutagenesis of the LCMV and MOPV.

S2 Table. Oligomers names and sequences.

S3 Table. Comparison of remaining sequence length function of time.

S4 Table. Observed S segment mutations of WT and ExoN(-) viruses at passages #1 and #10.

Figure1


A
NP-exo MOPV
HP4
*5'
3'
NP-exo LCMV
Mg2+
Mn2+
Zn2+
Ca2+
EDTA
0.1 5 30
0 0.1 5 30
min
nts
22
20
18
16
B
NP-exo MOPV
NC
WT
D390A
E392A
D467A
H529A
D534A
NP-exo LCMV
D382A
E384A
D459A
H517A
D522A

Figure 2


20
10
0
-10
-20
Change in melting temperature (°C))
Mn2+
Mg2+
Zn2+
Ca2+
NP-exo MOPV
NP-exo LCMV

Figure 3


NP-exo MOPV
HP4
0 0.1 5 30
nts
22
20
18
LE19
0 5 30
nts
19
17
A30
0 5 30 min
nts
30
NP-exo LCMV
HP4
0 0.1 5 30
nts
22
18
LE19
0 5 30
nts
19
17
A30
0 5 30 min
nts
30

Figure 4


A
5'*
3'-P
A A U U
5'
RL2*/RT1
G
RL3*/RT1
C
RL4*/RT1
U
RL5*/RT1
B
NP-exo MOPV
NP-exo LCMV
RL2*/RT1
RL3*/RT1
RL4*/RT1
RL5*/RT1
0 1 2 5 10 min
nts
22
20
16
10
3
1
C
Total product concentration (nM)
Time (min)
RL2*/RT1
RL3*/RT1
RL4*/RT1
RL5*/RT1

Figure 5


A
N
β9
β8
β1
β5
β6
α4
E
E
D
β10
β7
β2
β3
β4
η2
D
α6
α1
α2
α5
C
α3
B
β7
β6
α5
η2
α4
D
E
α2
D
β2
β5
β4
β1
β3
η2
η2
D
α6
α1
N
C
α3
C
α4
β4/3
β3/2
β2/1
E
E
D
D
D
β7/4
β10/5
α6

Figure 6


A
MOPV$_{WT}$ ffu
MOPV$_{WT}$ rna
MOPV$_{D390A/G393A}$ ffu
MOPV$_{D390A/G393A}$ rna
FFU/mL
NP RNA copies/mL
Passage
B
MOPV$_{WT}$
MOPV$_{D390A/G393A}$
ratio RNA copies / FFU
Passage

Figure 7


Mammarenavirus
Lassa Virus
Mopeia Virus
S184L
S 69 %
Q 10 %
F 7 %
H 4 %
V 3 %
E 1 %
L 1 %
NIADK < 1 %
S 94 %
V 4 %
L 1 %
IA < 1 %
S1021P
P 61 %
H 11 %
S 11 %
V 9 %
L 2 %
T 1 %
I 1 %
FDQE < 1 %
P 82 %
H 14 %
S 3 %
QN < 1 %
L1477S
L 96 %
G 4 %
probability

	Passage #01					
	position*	ref	mut	region	residue	frequency %
MOPV WT	9	A	G	5'UTR		12,500
	12	A	G	5'UTR		13,580
	742	A	T	Lpol	M229L	10,096
	1733	T	C	Lpol	L559S	6,140
	2463	T	A	Lpol	F802L	6,058
	2524	A	G	Lpol	T824A	6,043
	4473	C	T	Lpol	P1471P	12,058
	4663	T	G	Lpol	L1536V	11,227
	4691	A	T	Lpol	K1545M	6,941
	5471	T	A	Lpol	V1805E	9,798
	6251	C	T	Lpol	P2065L	8,235
	6259	G	C	Lpol	D2068H	9,002
	6452	A	G	Lpol	E2132G	9,379
	6564	A	G	Lpol	G2169G	6,528
	6746	T	G	Lpol	V2230G	18,750
	6903	A	G	Z	N97N	5,769
	7262	T	G	3'UTR		7,692

Passage #10					
position*	ref	mut	region	residue	frequency %
5	A	G	5'UTR		12,500
9	A	G	5'UTR		6,122
735	T	C	Lpol	N226N	5,430
792	T	C	Lpol	F245F	6,667
817	A	G	Lpol	I254L	25,411
1024	C	T	Lpol	H323Y	7,478
1097	G	A	Lpol	R347K	5,144
1397	G	A	Lpol	S447N	6,585
1834	C	T	Lpol	P593S	23,560
2212	T	G	Lpol	F719V	6,263
2233	G	A	Lpol	D726N	7,390
2463	T	A	Lpol	F802L	7,765
2840	A	G	Lpol	D928G	15,826
3217	C	T	Lpol	Q1054Stop	5,810
4498	G	A	Lpol	D1480N	5,200
4868	G	A	Lpol	S1604N	8,793
5407	G	T	Lpol	A1784S	24,272
5422	A	G	Lpol	R1789G	16,089
5992	G	C	Lpol	V1979L	6,454
6024	A	T	Lpol	S1989S	8,835
6268	C	T	Lpol	P2071S	8,788
6302	A	T	Lpol	D2082V	12,893
6406	T	C	Lpol	F2117L	5,393
6602	G	T	Lpol	R2182I	10,453
6769	T	G	Lpol	Stop-E	11,724
6802	C	T	IGR		9,524
6965	G	T	Z	P77S	6,856
6990	C	A	Z	R68M	11,690
6992	T	G	Z	D67D	11,761
7017	A	T	Z	L59L	7,450
7020	A	T	Z	C58C	7,471
7099	C	A	Z	G32A	7,673

	Passage #01					
	position*	ref	mut	region	residue	frequency %
MOPV Exo (-)	9	A	G	5'UTR		16,667
	12	A	G	5'UTR		12,121
	17	A	G	5'UTR		5,036
	742	A	T	Lpol	M229L	5,552
	2463	T	A	Lpol	F802L	5,583
	2518	T	C	Lpol	L822L	6,373
	6452	A	G	Lpol	E2132G	5,816
	6602	G	T	Lpol	R2182I	5,553
	6870	C	T	IGR		12,903
	6990	C	A	Z	R68M	7,550
	6992	T	G	Z	D67D	7,462

Passage #10					
position*	ref	mut	region	residue	frequency %
5	A	C	5'UTR		8,333
5	A	G	5'UTR		8,333
9	A	G	5'UTR		6,122
129	A	C	Lpol	K23N	6,522
608	C	T	Lpol	S184L	93,178
1456	A	T	Lpol	R467W	24,704
2079	T	C	Lpol	D674D	6,373
2233	G	A	Lpol	D726N	6,045
2427	G	A	Lpol	V790V	7,237
2622	T	C	Lpol	D855D	9,348
3118	T	C	Lpol	S1021P	58,105
3163	A	T	Lpol	T1036S	5,868
3624	T	C	Lpol	N1189N	8,228
4487	T	G	Lpol	L1477W	10,772
4500	T	A	Lpol	D1480D	5,134
4883	A	G	Lpol	L1477S	60,227
5239	G	A	Lpol	E1728K	8,367
6302	A	T	Lpol	D2082V	6,604
6567	A	T	Lpol	R2169R	9,287
6729	G	C	Lpol	R2225S	9,980
6769	T	G	Lpol	Stop-E	6,829
6772	G	A	IGR		9,596
6870	C	T	IGR		6,667
6965	G	T	Z	L76L	6,655
7032	T	C	Z	L54L	27,373

* position number correspond to antigenome sens numbering

mutations present in both segments of the two viruses at passages 01 and 10

mutations present in one segment of both viruses at passage 10

non-synonymous mutations that became majority at passage 10

Table 1 : Observed mutation between WT and Mutant Exo (-) of segment L at passages #1 and #10.